Anzeige
Mehr »
Login
Samstag, 29.03.2025 Börsentäglich über 12.000 News von 696 internationalen Medien
Ad-hoc-News: Wieder Verdopplung? Montag massiver Turnaround und komplette Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2N5R0 | ISIN: US9842411095 | Ticker-Symbol:
NASDAQ
28.03.25
20:43 Uhr
4,800 US-Dollar
-0,160
-3,23 %
1-Jahres-Chart
Y-MABS THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
Y-MABS THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur Y-MABS THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
21.03.Breaking Down Y-mAbs Therapeutics: 5 Analysts Share Their Views1
13.03.Pre-market Movers: Y-mAbs Therapeutics, Aveanna Healthcare, UiPath, Exicure, CareCloud442SANTA CLARA (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.55 A.M. ET).In the Green Aveanna Healthcare Holdings Inc. (AVAH) is up...
► Artikel lesen
06.03.Y-mAbs Therapeutics (NASDAQ:YMAB) Given New $7.00 Price Target at Morgan Stanley5
05.03.Forecasting The Future: 4 Analyst Projections For Y-mAbs Therapeutics3
05.03.Jones Trading cuts YMAB stock target to $18, maintains Buy1
Y-MABS THERAPEUTICS Aktie jetzt für 0€ handeln
04.03.Morgan Stanley cuts YMAB stock price target to $7 from $113
04.03.BofA cuts YMAB stock target to $12 on slower Danyelza launch5
04.03.Y-mAbs stock price target cut to $19 at Cantor Fitzgerald-
04.03.Clear Street cuts YMAB stock target to $18, maintains Buy1
04.03.Y-mAbs Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans-
04.03.Y-mAbs Therapeutics misses Q4 top-line and bottom-line estimates; initiates Q1 and FY25 outlook1
04.03.Y-mAbs Therapeutics, Inc.: Y-mAbs Reports Fourth Quarter 2024 Financial Results and Recent Corporate Developments828Reported Total Revenues of $26.5 million for the fourth quarter of 2024 and $87.7 million for the full year 2024 The Company established two business units in January 2025 aimed to accelerate the...
► Artikel lesen
04.03.Y-mAbs Therapeutics, Inc. - 10-K, Annual Report-
04.03.Y-mAbs Therapeutics, Inc. - 8-K, Current Report-
03.03.Y-mAbs Therapeutics, Inc.: Y-mAbs Announces Publication of Phase 2 Interim Results in Nature Communications437NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization...
► Artikel lesen
20.02.Y-mAbs Therapeutics, Inc.: Y-mAbs to Announce Fourth Quarter and Full Year 2024 Financial and Operating Results on March 4, 20252
31.01.Y-mAbs Therapeutics, Inc.: Y-mAbs Presents Translational Pharmacokinetics of GD2-SADA from Pretargeted RIT Platform at the SNMMI Mid-Winter and ACNM Annual Meeting2
13.01.Y-mAbs splits from commercial chief, tasks new hire with growing cancer drug sales4
10.01.IGM, Y-mAbs, Passage Bio and more telegraph staff cuts amid restructuring spree2
10.01.Y-mAbs Therapeutics guides FY2024 revenue below estimates1
Seite:  Weiter >>
44 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1